OFFER DEADLINE21/08/2021 12:00 - Europe/Brussels
EU RESEARCH FRAMEWORK PROGRAMMEHE / MSCA
ORGANISATION/COMPANYInternational Research Projects Office
DEPARTMENTPromotion and Advisory Unit
Professor Pedro Pablo Medina Vico from the Department of Biochemistry and Molecular Biology I at the University of Granada, welcomes postdoctoral candidates interested in applying for a Marie Skłodowska-Curie Postdoctoral Fellowships (MSCA-PF) in 2021 at this University. Please note that applicants must comply with the Mobility Rule (more information about the 2020 call: http://sl.ugr.es/0aNV, the 2021 call is not yet open).
Brief description of the institution:
The University of Granada (UGR), founded in 1531, is one of the largest and most important universities in Spain. With over 60.000 undergraduate and postgraduate students and 6.000 staff. UGR offers a total of 89 degrees, 110 master’s degrees and 28 doctoral programmes through its 123 departments and 27 centers. Consequently, the UGR offers one of the most extensive and diverse ranges of higher education programmes in Spain.
The UGR has awarded with the "Human Resources Excellence in Research (HRS4R)", which reflects the UGR’s commitment to continuously improve its human resource policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. UGR is also a leading institution in research, located in the top of Spanish universities by a variety of ranking criteria, such as national R&D projects, fellowships awarded, publications, or international funding. UGR is one of the few Spanish Universities listed in the Shanghai Top 500 ranking - Academic Ranking of World Universities (ARWU) (http://sl.ugr.es/0bsW). The UGR is amongst the 201-300 first universities of the world, between 2nd-5th position of Spanish universities and number 1 in the Andalusian Region in the Shanghai Top 500 ranking. Specialties at UGR that stand out are Library & Information Science (position 32) and Food Science & Technology (position 36). Moreover, the UGR is also situated amongst the first 100 universities in Mining & Mineral Engineering between (76th-100th position), in Mathematics (between 76th-100th position) and in Hospitality & Tourism Management (between 76th-100th position). The edition of the ARWU places the UGR in 201-300th position in the world and as the 4th highest ranked University in Spain, reaffirming its position as an institution at the forefront of national and international research.
Additionally, the UGR has 8 researchers at the top of the Highly Cited Researchers (HCR) list in Computer Sciences & Engineering (position 101-150). It is also well recognized for its web presence (http://sl.ugr.es/0a6i), being positioned at 43th place in the top 200 Universities in Europe.
Internationally, we bet decidedly by our participation in the calls of the Framework Programme of the European Union. For the duration of the last two Framework Programmes, the UGR has obtained a total of 67 projects, with total funding of 18.029 million euros, and for H2020, 118 projects with total funding around 29.115 million euros.
Brief description of the Centre/Research Group:
Group CTS-993. GENE EXPRESSION REGULATION increases the functional versatility and adaptability of the cell by allowing it to express certain proteins when needed. It is, therefore, one of the most important and complex processes of biology. Changes in the gene expression patterns are key in cancer cell transformation, through an increase in expression of genes that promote carcinogenesis (oncogenes) and/or a decrease in expression of genes that prevent it (tumour suppressor genes). Non-coding RNAs and chromatin-structure both play important roles in this process and have been found to be critical in the development of human pathologies. Both of these regulatory elements, especially in the context of CANCER, have been the focus of my interest during my career.
The SWI/SNF complex is an ATP-dependent chromatin-remodelling complex that is known to regulate EPIGENETICALLY the gene expression (Kwon, Imbalzano et al. 1994). Increasing evidence demonstrates that some components of the SWI/SNF complex are tumour suppressors and are involved in human cancer development. One subunit of this complex, SNF5, is inactivated in malignant rhabdoid tumours (MRTs) and heterozygous Snf5 knockout mice develop tumours that are histologically similar to human MRTs (Roberts, Galusha et al. 2000; Roberts, Leroux et al. 2002). BRG1 (Medina and Sanchez-Cespedes 2008), the helicase/ATPase catalytic subunits of the SWI/SNF complex, is mutated in many different cancer cell lines (Wong, Shanahan et al. 2000; Medina, Romero et al. 2008). Additionally, germline BRG1 mutations linked to a Rhabdoid Tumour Predisposition Syndrome was reported in a family, strongly suggesting that is a bona fide tumour suppressor gene (Schneppenheim, Fruhwald et al.). Recently, it has been discovered that two other subunits of the chromatin-remodelling complex, BAF250 (ARID1A) and BAF180 (PBRM1) (Jones, Wang et al. ; Wiegand, Shah et al. ; Varela, Tarpey et al. 2011; Wilson and Roberts 2011), are frequently mutated in ovarian clear cell carcinoma and renal carcinoma, respectively. All these observations support an important role of the SWI/SNF complex in cancer, however its specific function is still unclear.
MiRNAs are a recently discovered class of small RNA molecules that regulate gene expression at the post-transcriptional level. Due to their small size and unusual nature, miRNAs were not discovered in humans until 2000. Today, over one thousand miRNAs have been identified in the human genome. Aberrant biogenesis and/or expression of miRNAs have been linked to human diseases including cancer (Medina and Slack 2008). During my training as a postdoc in this field I have helped to reveal the critical role played by specific miRNAs in cancer. While most previous studies in the field used cell lines or in vitro systems, we pioneered the functional study of the role of miRNAs using in vivo transgenic mouse models. We demonstrated the therapeutic utility of let-7 microARN ectopic expression in vivo (Medina, Trang et al. 2010), and the important of a single microARNs (miR-21) to the drive of tumor development (Medina, Nolde et al. 2010). In my recently created group at the GenyO Center we will continue unveiling the role of the microRNAs and other non-coding RNA species in cancer with the hope to find novel and useful cancer therapies.
- Life Sciences (LIFE)
For a correct evaluation of your candidature, please send the documents below to Professor Pedro Pablo Medina Vico (email@example.com):
- Letter of recommendation (optional)
The responsibility for the hosting offers published on this website, including the hosting description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.